Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05011279
Other study ID # 20-104
Secondary ID U54CA156732
Status Completed
Phase N/A
First received
Last updated
Start date September 10, 2021
Est. completion date January 21, 2022

Study information

Verified date November 2023
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to develop and test a mobile app for Black/African American breast cancer survivors and their relatives, called Move Together, that promotes sitting less and moving more for better health.


Description:

The purpose of this study is to develop and test a mobile app for Black/African American breast cancer survivors and their relatives, called Move Together, that promotes sitting less and moving more for better health. This is a cross-sectional descriptive study using structured interviews and qualitative data analysis to develop an intervention, followed by a pilot test of the intervention with pre- /post- measures. - In study phase 1,involved qualitative interviews with 5 community leader key informants, 9 breast cancer survivors and 6 first degree relatives of a survivor. - This part of the research study is a Pilot Study, which means it is the first time that researchers are studying usability and acceptability of the Move Together app. - Participants in the pilot study will participate as members of family-based dyads (n=10 dyads). One member of each dyad will be a breast cancer survivor and one will be a blood relative - Study involves screening for eligibility, interviews, questionnaires, Use of Move Together app with Garmin activity tracker watch - Participation on the trial will be for 5 weeks - About 20 people (10 survivors with 10 relatives) will participate in this part of the study, and a total of 58 people in the whole study.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date January 21, 2022
Est. primary completion date January 21, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1a) Key informants (for interviews) - Members of the community/advisory groups, community health centers, or faith-based network members (e.g., Pink and Black, Faces of Faith). - English speaking adults. - (1b) Breast cancer survivors and relatives (for interviews) - Self-identify as Black or African American - Age 18 and over - English speaking - Female breast cancer survivor status post curative antineoplastic treatment (except ongoing hormonal treatment) with no evidence of disease, OR a first degree blood relative (parent, child, or full sibling), of any gender, of a so defined breast cancer survivor - Self-report ever using a smart phone - (2) Breast cancer survivors and relatives (for user testing/interviews) - Self-identify as Black or African American - Age 18 and over - English speaking - Female breast cancer survivor status post curative antineoplastic treatment (except ongoing hormonal treatment) with no evidence of disease, OR a first degree blood relative (parent, child, or full sibling), of any gender, of a so defined breast cancer survivor - Self-report willing/able to download the app for testing on a smart phone - Self-report willing/able to meet via Zoom for interview - (3) Breast cancer survivors and relatives/"buddies" (for pilot testing) - Self-identify as Black or African American - Age 18 and over - English speaking - Breast cancer survivor status post curative antineoplastic treatment (except ongoing hormonal treatment) with no evidence of disease, OR a blood relative, of any gender, of a so defined breast cancer survivor - Self-report willing/able to participate with a blood relative in survivor relative dyad - Self-report willing/able to download the app for use on a smart phone - Self-report willing/able to meet via Zoom for instructions and interview Exclusion Criteria: - (1a) Key informants (for interviews) --None - (1b) Breast cancer survivors and relatives (for interviews) - Requires medically supervised physical activity (Physical Activity Readiness Question for Everyone, PAR-Q+, Question 7) - Pregnant women - (2) Breast cancer survivors and relatives (for user testing/interviews) - Requires medically supervised physical activity (Physical Activity Readiness Question for Everyone, PAR-Q+, Question 7) - Pregnant women - (3) Breast cancer survivors and relatives/"buddies" (for pilot testing) - Meets exclusion criterion of the Modified Physical Activity Readiness Questionnaire (PAR-Q) (modified) - Participated in interviews or user testing in prior phases of the study

Study Design


Intervention

Other:
Move Together app/Garmin Activity Tracker
The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links. Garmin activity tracker in this study is for participants to track their steps and sedentary time.

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts
United States University of Massachusetts Boston Boston Massachusetts
United States University of Rochester Rochester New York

Sponsors (4)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute National Cancer Institute (NCI), University of Massachusetts, Boston, University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary System Usability Scale (SUS) Score The acceptability of the Move Together app will also be assessed with The System Usability Scale (SUS) score. The scale has 10 items. Scores range from 0-100; a SUS score above a 68 is considered above average (https://www.usability.gov/how-to-and-tools/methods/system-usability-scale.html.) Assessed at 4 Weeks
Secondary Number of Participants Screened Per Month the number of participants screened per month during recruitment period (not cumulative) 4 month recruitment period
Secondary Number of Participants Enrolled Per Month number of participants consented to the study each month during enrollment period 4 month enrollment period
Secondary Completion Rate number of participants who completed all aspects of the protocol 4 Weeks
Secondary Number of Study Days number of study days in which the participants uses the Move Together app and will describe engagement with the app in a 28 day period (i.e., study days) baseline to 4 weeks (28 days)
Secondary Number of Participants Recruited Number of initial respondents who consent and enroll. during 4 month recruitment period
Secondary Number of Participants Completed Study Total number of participants who completed the study 4 weeks
Secondary Number of Participants Retained at the End of 4 Weeks Retention will be the number who remain in the study at the end of 4 weeks Baseline to 4 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A